BCL2 and diffuse large B-cell lymphoma: In this case report, a patient with primary refractory DLBCL/HGBL-MYC/BCL2 achieved PFS of over 7 months (ongoing) with glofitamab, exceeding the median OS of 6.3 months reported in the international SCHOLAR-1 study (11).